{{Rsnum
|rsid=7819412
|Gene=XKR6
|Chromosome=8
|position=11187652
|Orientation=plus
|GMAF=0.4725
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=XKR6
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 27.4 | 47.8 | 24.8
| HCB | 0.0 | 10.2 | 89.8
| JPT | 0.9 | 9.7 | 89.4
| YRI | 93.2 | 6.1 | 0.7
| ASW | 80.7 | 17.5 | 1.8
| CHB | 0.0 | 10.2 | 89.8
| CHD | 0.0 | 9.3 | 90.7
| GIH | 35.6 | 45.5 | 18.8
| LWK | 90.9 | 9.1 | 0.0
| MEX | 13.8 | 37.9 | 48.3
| MKK | 67.9 | 29.5 | 2.6
| TSI | 27.5 | 53.9 | 18.6
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=19060906
|Trait=Triglycerides
|Title=Common variants at 30 loci contribute to polygenic dyslipidemia
|RiskAllele=G
|Pval=3E-8
|OR=0.04
|ORtxt=[0.001-0.08] SD decrease
|OA=1
}}

{{PharmGKB
|RSID=rs7819412
|Name_s=
|Gene_s=XKR6
|Feature=
|Evidence=PubMed ID:19060906; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Common variants at 30 loci contribute to polygenic dyslipidemia. (Initial Sample Size: 19,840 individuals; Replication Sample Size: Up to 20,623 individuals); (Region: 8p23.1; Reported Gene(s): XKR6, AMAC1L2; Risk Allele: rs7819412-G); (p-value= 0.00000003).This variant is associated with Triglycerides.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740268
}}

{{PMID|19364639|OA=1
}} The effect of a novel intergenic polymorphism (rs11774572) on HDL-cholesterol concentrations depends on TaqIB polymorphism in the cholesterol ester transfer protein gene.

{{PMID|19936222|OA=1
}} Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis.

{{PMID|20160193|OA=1
}} Investigation of variants identified in caucasian genome-wide association studies for plasma high-density lipoprotein cholesterol and triglycerides levels in Mexican dyslipidemic study samples.

{{PMID|20421936|OA=1
}} Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and german study groups.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7819412
|overall_frequency_n=71
|overall_frequency_d=126
|overall_frequency=0.563492
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=67
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}